SCHEMBL21300012

SCHEMBL21300012

BC(B)(O)N(C(=O)OC(C)(C)C)C(B)(B)c1ccc(/C(Cl)=N/O)cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20746768 0.91 ELANE (0.30) —
SCHEMBL20746747 0.85 ELANE (0.31) —
SCHEMBL21299986 0.78 ELANE (0.31) —
SCHEMBL21698575 0.77 HDAC3 (0.37) —
SCHEMBL20746766 0.72 HDAC3 (0.38) —
SCHEMBL14829667 0.70 ALDH1A1 (0.40) —
SCHEMBL14838574 0.70 ALDH1A1 (0.40) —
SCHEMBL20746753 0.69 MIF (0.37) —
SCHEMBL21698572 0.69 ELANE (0.32) —
SCHEMBL24038574 0.68 HDAC1 (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940017-B1 Process for making compounds useful as inhibitors of ATR kinase VERTEX PHARMA (US) 2019-08-28 — — EP disclosed
Send feedback